| Name | Title | Contact Details |
|---|
Astellas Pharma US, Inc., a U.S. affiliate of Tokyo-based Astellas Pharma Inc., is a pharmaceutical company dedicated to changing tomorrow by improving the health of people around the world through innovative and reliable pharmaceutical products. In 2005, Astellas was formed by blending the talents, resources and passions of two highly successful firms - Yamanouchi and Fujisawa. Astellas aims to maintain and strengthen our position as the global leader in transplantation and urology areas, and going forward we are working to establish our position as a global category leader in oncology. At all levels throughout the company our people are committed to the opportunity to positively affect and improve patient lives while remaining socially responsible to our community and those with whom we work and collaborate.
Halo Pharmaceutical is a contract development and manufacturing organization (CDMO) that provides scientific, regulatory and development expertise as well as a wide spectrum of manufacturing services to help customers bring their products to market quickly, effectively and on budget. Halo offers fully integrated capabilities in a variety of dosage forms including tablets, capsules, powders, liquids, creams, sterile and non sterile ointments and suppositories. The company is registered to work with any of these dosages in the CI-CV designations. Halo Pharmaceutical’s capabilities in the areas of tech transfer, process and product development, production, scale-up and validation and analytical method development allow us to partner with clients from development through commercialization or at any point along the way.
Champions Oncology is a company that develops technology solutions and services for personalizing the development and use of oncology drugs. Their technology-enabled research platforms empower biopharma to create a comprehensive understanding of tumor ...
Albany Molecular Research is a Albany, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Olema is a preclinical biotechnology company developing new drugs for the treatment and prevention of estrogen receptor (ER) positive breast cancer. At Olema we leverage the exquisite knowledge of the molecular action of the ER to design compounds that are superior to both the current drugs and those in development.